Laekna Therapeutics

Laekna Therapeutics, founded in 2016, is a global biopharmaceutical technology company at the clinical stage, committed to bringing breakthrough therapies to cancer and liver fibrosis patients worldwide. The company currently has two potential core products: LAE002, a highly selective ATP-competitive AKT inhibitor, is being developed for the treatment of ovarian cancer, prostate cancer, breast cancer, and PD-1/PD-L1 resistant solid tumors. Another core product, LAE001, is a potential first-in-class next-generation androgen synthesis inhibitor that simultaneously inhibits CYP17A1 and CYP11B2, and is under development for the treatment of prostate cancer. Based on strong R&D capabilities, Laekna Therapeutics is rapidly advancing the development of 14 innovative candidate products in its pipeline. For the potential core products, the company is actively promoting one pivotal clinical trial and five clinical trials, three of which are international multicenter clinical trials (MRCT), aiming to address the urgent but unmet global medical need of resistance to standard-of-care (SOC) cancer treatments. In the field of independent research and development, Laekna Therapeutics focuses primarily on treating cancer and liver fibrosis by modulating the human immune system.